Separate names with a comma.
Discussion in 'Stock Market Today' started by Stockaholic, Jun 3, 2018.
I'm liking AVXL right now above $15
ORGO has been a good stock for a while, and it started the month with 4x normal volume.
I have 5k to invest within my self directed ira. Was looking at arkk but more likely am thinking xtn which is a transportation etf.
SAIA looks okay in XTN.
Lots of airlines in XTN, and I think they will be good in 2022.
Yup. And the dow transportation index ytd results are much higher than the dow as a whole
Many which I have on my potfolio get red yesterday and lost about 10% average
The US Consumer Products Safety Commission tweeted an alert that people with children should not have the Peloton Tread+, with video.
March's high of 126.74 is a clear exit for a short; it failed to reach that on Tuesday.
Also a tweezer top in the last 2 weekly candles.
anybody in favor of the government staying out it and letting evolution do its thing?
People with children should get enough exercise just chasing after those rugrats anyhow.
CAMT reports this week, would like to see it make higher highs and lows each day to keep this bounce off the 50 sma going.
MNMD on Tuesday when MindMed gets on the NASDAQ. Current tickers is MMEDF on the OTC. Uplist happened on Friday.
Watching klic with great anticipation. I have a big position in it and will be adding to it this week.
Closed CAMT, not liking the resistance at the month's high.
Earnings tomorrow morning probably take it back toward the month's low.
Coinbase Shares Up 1.7%; BTIG Research Sets $500 Price Target
9:50 am ET April 30, 2021 (Benzinga) Print
Latest Ratings for COIN DateFirmActionFromTo
Apr 2021BernsteinInitiates Coverage OnMarket Perform Apr 2021MizuhoInitiates Coverage OnNeutral Apr 2021RosenblattInitiates Coverage OnBuy
View More Analyst Ratings for COIN
View the Latest Analyst Ratings
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
AGIO has an investor webcast on the 11th, and on the 15th they present data for mitapivat at the European Hematology Association Annual Congress.
CLOVER HEALT #CLOV
Shorted due to hindenburg report with 3 claims: 1) claim of owning a subsidairy in insurance 2) growth not represented good enough 3) an SEC investigation...all are to say the least very sketsy but here are fundamentals
1) loved by wallstreetbets
2) shorted by over 40%....and due to retail and institutional interest little free float available
3) will be in russel MSCI index as of 25 of june meaning Funds and ETFs need to buy
4) bad news / short report already priced in as shares dropped from $25 to $9
5) growth company in government health care...steady business...low risk...fundamentals great
6) growth on target for 2021 + 30%..
7) owners can only get out if share price is higher than 30$ for 3 months...so ...
Eitherway...this might be a short squeeze 2.0 or just on the bases of fundamentals it is a great company
I'm thinking about ILUS and MVIS for next week. I'm going to add them to my BTCS, EEENF portfolio. Just got on the pc today and will probably browse some more for other interesting stocks to check.
PGNY is profitable already and has a 60% growth rate.
CTXR no doubt,
over 100m in cash, data read out in 9 days
CNC is testing ATHs, third time at this top going back to 2018